Corbus Pharmaceuticals Holdings, Inc. (CRBP)

Market Cap	620.47M
Revenue (ttm)	n/a
Net Income (ttm)	-33.76M
Shares Out	10.69M
EPS (ttm)	-6.94
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	226,885
Open	56.70
Previous Close	55.45
Day's Range	56.22 - 59.72
52-Week Range	3.03 - 61.18
Beta	2.59
Analysts	Strong Buy
Price Target	74.60 (+28.49%)
Earnings Date	Aug 6, 2024

About CRBP

Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFβ expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonis...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2009
• Employees: 19
• Stock Exchange: NASDAQ
• Ticker Symbol: CRBP

Analyst Forecast

According to 5 analysts, the average rating for CRBP stock is "Strong Buy." The 12-month stock price forecast is $74.6, which is an increase of 28.49% from the latest price.

Price Target

$74.6

(28.49% upside)

Analyst Consensus: Strong Buy